These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 23208128

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T.
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT, Chang JW, Liu HP, Yu TF, Chiu YT, Hsieh JJ, Chen YT, Chen YR, Wu HD, Huang SF.
    J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
    [Abstract] [Full Text] [Related]

  • 32. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F.
    Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
    [Abstract] [Full Text] [Related]

  • 33. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.
    Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Manríquez ME, Covián-Molina E, Martínez-Barrera L, Meneses A, Cardona A, Borbolla-Escoboza JR.
    J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [Abstract] [Full Text] [Related]

  • 40. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.